Federal lawsuit targets largest cannabis companies for alleged false marketing

In a significant legal development, a federal class action lawsuit has accused three of the largest players in the recreational cannabis industry of using a "concerted campaign" to misrepresent their products as beneficial medicines. The suit, filed in the United States District Court for the Northern District of Illinois, targets Cresco Labs Inc., Green Thumb Industries Inc., and Verano Holdings, all headquartered in Illinois.

The lawsuit, which was filed on May 4, 2026, by plaintiffs against the defendants, names 41 putative class representatives from 12 states. The case centers on alleged false and misleading marketing practices that suggest recreational cannabis products have therapeutic benefits and can be used as medicine. According to the plaintiffs, these claims are pervasive and not limited to specific products, but rather are disseminated through the defendants' websites, blogs, social media, and other marketing materials.

Specifically, the plaintiffs point to marketing materials that claim cannabis can provide therapeutic benefits for conditions like PTSD, migraines, chronic pain, and inflammation. They also allege that defendants falsely claim their dispensaries employ "cannabis pharmacists" with specialized knowledge in medical cannabis and that strains of cannabis are marketed for managing anxiety and stress or treating depression. The plaintiffs further accuse the defendants of creating and publishing pseudo-research to support these claims.

The defendants, Cresco Labs Inc., Green Thumb Industries Inc., and Verano Holdings, have filed a motion to dismiss the case. In their opposition, the plaintiffs argue that the alleged misrepresentations are part of a broader marketing campaign rather than individual product issues, making the exact number of products manufactured and sold irrelevant to the scope of discovery. They request limited discovery to include the negotiation and submission of a protective order and an electronically stored information (ESI) protocol, as well as the service of initial Requests for Production and the negotiation of search terms and custodians.

The case highlights the complex interplay between federal policy and the cannabis industry. On April 2026, the federal government extended Schedule III treatment to marijuana subject to a qualifying state medical marijuana license. This move has significant economic implications, including the potential for state-licensed operators to avoid the high tax rates imposed by Section 280E of the Internal Revenue Code, which disallows business deductions for trafficking in controlled substances.

Additionally, the rescheduling has led to expedited federal registration processes and increased access to capital markets. In May 2026, Green Thumb Industries publicly announced its application for DEA registration under the new framework. The first U.S.-operating cannabis company began trading on a major U.S. exchange in June 2026, marking a significant milestone in the industry's access to institutional investment and lower-cost capital.

Duane Boise, President and CEO of MMJ International Holdings, commented on the legal dispute, stating, "It is a discovery dispute in a case that may not survive a motion to dismiss. It is not a finding, and I am not going to pretend otherwise. What makes it worth noticing is the timing. The federal government has conferred the legitimacy and the economics of medicine on an industry while a federal court is being asked to decide whether that same industry's medical claims can be examined in discovery."

MMJ International Holdings, which has pursued FDA botanical drug development exclusively through federal pathways for more than eight years, holds a DEA Schedule I analytical laboratory registration and is pursuing Investigational New Drug programs for Huntington's disease and multiple sclerosis. The company emphasizes the importance of an evidence-based framework and opposes what it sees as "bad science and fake process."

The legal battle underscores the ongoing tension between industry marketing practices and the scientific validation of cannabis's medical benefits.